Analysis of Cytokines in Serum and Bronchoalveolar Lavage Fluid in Patients with Immune-Checkpoint Inhibitor Associated Pneumonitis: a Parallel Cohort Study

Benedikt Kowalski  
University Hospital Zurich: UniversitatsSpital Zurich

Alan Valaperti  
University Hospital Zurich: UniversitatsSpital Zurich

Urs C Steiner  
University Hospital Zurich: UniversitatsSpital Zurich

Dieter Scholtze  
Municipal Hospital Triemli: Stadtspital Triemli

Stephan Wieser  
Municipal Hospital Waid: Stadtspital Waid

Maya Vonow-Eisenring  
University Hospital Zurich: UniversitatsSpital Zurich

Andrea Widmer  
University Hospital Zurich

Pascal Bezel  
University Hospital Zurich

Malcolm Kohler  
University Hospital Zurich

Daniel Franzen (✉ daniel.franzen@usz.ch)  
UniversitatsSpital Zurich  https://orcid.org/0000-0001-6080-9555

Research

Keywords: Immune-checkpoint inhibitor associated pneumonitis, bronchoalveolar lavage, cytokine profile, interleukin 6

DOI: https://doi.org/10.21203/rs.3.rs-129954/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Immune-checkpoint inhibitors (ICI) present a new treatment for malignancies by boosting the immune system. This has led to a variety of immune-related adverse events, including ICI-associated pneumonitis (IClA-P). Diagnosis thereof is often challenging, and its pathogenesis has not yet been fully understood. The aim of this parallel cohort study was to investigate cytokines in serum and bronchoalveolar lavage fluid (BALF) expressed in patients with ICI-associated pneumonitis compared to healthy individuals.

Methods

From January 2018 until June 2019, 401 adult patients with various lung diseases were prospectively enrolled in a BALF- and serum biobank, called BALOTHEK. Of these, 12 patients were diagnosed with IClA-P (Pembrolizumab, Ipilimumab, or both, and Durvalumab) and included in this parallel cohort study. Additionally, 12 healthy subjects from the biobank served as matched control group. The following 11 cytokines were simultaneously analyzed in BALF and serum of each study participant: interferon gamma, tumor necrosis factor alpha, interleukin (IL) 1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12p70, IL-13 and IL-17A. This study was approved by the local ethic review committee (BASEC-ID 2017-02307 and 2018-01724).

Results

Absolute number and percentage of lymphocytes in BALF of patients with IClA-P were significantly higher compared to control group. For the investigated cytokines in serum and BALF, a significant increase of IL-6 levels was shown for patients with IClA-P (p=0.044, adjusted for multiple comparisons).

Conclusion

Cytokine profile assessed in BALF shows promising potential for facilitating diagnosis and understanding of pathophysiology of IClA-P. IL-6 may not only contribute to better understanding of pathophysiology but also herald therapeutic implications for Tocilizumab.

Background

Both, chemo- and radiation therapy used to be the common approach for cancer treatment throughout decades. Recently, immune-checkpoint inhibitors (ICI) made of monoclonal antibodies (mAB) against receptors on T-lymphocytes have been introduced as a new therapeutic ideology in fighting cancer. Ipilimumab was the first ICI to be approved, representing a breakthrough in the treatment of metastatic melanoma [1]. Since then, clinical practice has changed [2] and new ICIs allowed treatment of various malignancies other than melanoma. Currently, there are two targetable immune checkpoints: cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the axis programmed cell death protein 1 (PD-1) and PD-1 ligand (PD-L1). Instead of repeated exposure to cytotoxic agents in traditional chemotherapy, ICIs boost the immune system by “inhibiting the inhibition” and, thus, helping it to tackle neoplasia effectively [3].
Compared to chemotherapy, the side effects of ICIs are different. Whereas adverse events from chemotherapy are partially caused by a compromised immune system, those caused by immunotherapy are mainly due to immune reinforcement. Thus, autoimmunity and excessive inflammatory responses referred to as immune-related adverse events (irAE) may be induced, leading to gastrointestinal, cutaneous, endocrinal and pulmonary manifestations, among others [4]. Pneumonitis is an uncommon, but potentially life threatening irAE. The reported incidence for pneumonitis is 1.3–11% for ICI monotherapy [5] and 6.6% for combination therapy of Ipilimumab with Pembrolizumab or Nivolumab [6].

The clinical presentation of ICI-associated pneumonitis is non-specific and heterogeneous, ranging from asymptomatic, only radiological manifestations to mild or moderate symptoms with cough and dyspnea, and, eventually, to very severe cases of acute respiratory distress syndrome (ARDS) [7–9]. While computed tomography (CT) is indispensable for diagnosis, imaging of pneumonitis is also unspecific and includes various patterns of interstitial lung disease (ILD), such as organizing pneumonia (OP), non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonitis (HP), acute interstitial pneumonia (AIP) and usual interstitial pneumonia (UIP) [10, 9, 11]. Median onset has been observed at 2.5 months after initiation of ICI therapy, with a time window ranging between 2 and 24 months [4, 9]. All the above mentioned factors may contribute to delayed diagnosis of ICI-associated pneumonitis, while pathogenesis has not yet been fully understood.

Since ICI-associated pneumonitis is thought to result from immune driven over-reaction, changes in cytokines as immunomodulatory proteins produced by immune cells among others can be expected. While a recent study [12] successfully identified 11 cytokines in serum to predict irAE, data about cytokines expressed in pneumonitis are scarce. However, cytokines measured only in serum might be misleading in determining type and degree of inflammation in a specific organ. Various studies suggest organ specific sample collection as the best method for exact and targeted assessment [13–17]. Flexible bronchoscopy is an established diagnostic tool for a broad range of pulmonary diseases, since it enables minimally invasive biopsies at low risk for various techniques including (BAL) [18–20]. Therefore, BAL appears suitable to provide more detailed information on the lung tissue by obtaining bronchoalveolar lavage fluid (BALF).

The aim of this parallel cohort study was to investigate cytokines in serum and BALF expressed in patients with ICI-associated pneumonitis compared to healthy individuals. To the best of our knowledge, there is only one study [21] investigating cytokine expression in BALF in patients with ICI-associated pneumonitis.

**Materials And Methods**

**Patients**

The present study is part of a prospective multicenter study, which aims to establish a biobank ("BALOTHEK") using blood serum and BALF for the research of various lung diseases. The samples were
acquired from patients in whom BAL was performed for purpose of routine clinical evaluation (BASEC-ID 2017–02307 and 2018–01724). Enrolled patients were retrospectively clustered in five groups according to clinical and radiological presentation, confirmed by histology: lung cancer, sarcoidosis, ILD, drug-related pneumonitis and chronic cough. Patients in the latter group served as healthy controls, when there were no pathological findings in the chest CT during a follow-up time of six months. Patients were excluded in case of precedent lung transplantation, general patient vulnerability such as emergencies or pregnancies and errors in sampling or processing of the samples, e.g. BAL to processing time exceeding 60 minutes [22].

From January 2018 until June 2019, a total of 401 adult patients were enrolled in BALOTHEK. Simultaneously, 240 patients were treated with ICIs at the Departments of Dermatology and Medical Oncology from University Hospital Zurich because of various malignancies. Of these 240 patients, 16 developed typical symptoms (i.e. cough, fever, dyspnea) and CT findings (i.e. COP, NSIP, HP, AIP) suggestive for ICI-associated pneumonitis. After conducting BAL however, in four patients an alternative diagnosis other than ICI-associated pneumonitis had been made (one patient with Melphalan-induced pulmonary toxicity, two patients with acute bronchitis and one patient with chronic cough of unknown origin). Thus, the remaining 12 patients were eventually included with the diagnosis of ICI-associated pneumonitis confirmed by BAL. From these patients BALF could be harvested for purpose of BALOTHEK and for the present study, respectively. In addition, 12 subjects from the control group of BALOTHEK, matched according to gender and age (range +/- five years) were used as healthy controls.

This parallel cohort study was approved by the local ethic review committee (BASEC-ID 2017–02307 and 2018–01724).

**Blood specimens and processing**

All blood samples were collected by nurses proficient in blood drawing as part of the routinely performed pre-interventional peripheral venous access. For differential blood count and whole blood count 10 ml BD Vacutainer K2E tubes (EDTA, Plus Blood Collection Tubes, Becton Dickinson, Plymouth, UK) were used. To gain serum samples, whole blood was collected in 10 ml BD Vacutainer Clot Activator Tube (CAT, Plus Blood Collection Tubes, Becton Dickinson, Plymouth, UK) and centrifuged at 3500 rounds per minute (rpm) at room temperature. Thereafter, the supernatant was aliquoted and eventually stored at −80 °C for later analyses, according to Valaperti et al. [22]. Once thawed for analysis, the samples were not frozen again.

**Bronchoscopy, BAL and processing of BALF**

Bronchoscopy was performed in moderate sedation with propofol using Olympus (Tokyo, Japan) flexible bronchoscopes (190 series). BALF was obtained conforming to official recommendations [23, 24] by instillation of isotonic saline solution in four times 50 ml portions into the wedged pulmonary segment
that showed the most prominent finding in the most recent chest CT. Through gentle suction of the same syringe that injected the solution, BALF was yielded and filled in designated tubes, absent any further substances such as anticoagulants and preservatives. The recovered BALF was quantitatively expressed in absolute values (ml) and in percent of the instilled volume. BALF was routinely used for cytological and microbiological analyses, whereas the rest served the purpose of this study. For processing, BALF was centrifuged at 1’000 rpm at room temperature, the supernatant was aliquoted and stored at -80 °C in accordance to Valaperti et al. [22]. Once thawed for analysis, the samples were not frozen again. The routinely performed analysis of BALF for cell differentiation was performed by ADVIA 2120i (Siemens Healthcare AG, Zurich, Switzerland) via peroxidase staining. Cell differentiation included cell count, macrophages, lymphocytes, neutrophils, eosinophils, mast cells, and plasma cells.

Cytokine analysis

A Milliplex MAP kit (human high sensitivity T cell magnetic bead panel) customized by Merk Millipore (Darmstadt, Germany) was used to analyze cytokines applying MAGPIX system (Luminex Corporation, Austin, TX, USA). The array contained the following 11 cytokines: interferon-gamma (IFN-gamma), interleukin (IL)-1B, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12p70, IL-13, IL-17, and tumor necrosis factor alpha (TNF-alpha). This selection of cytokines based on several publications [25–27, 12, 28] investigating inflammatory biomarkers in drug-induced pneumonitis as well as specifically ICI-associated pneumonitis. The preparation of standards was composed of serial dilution 1:4 of each stock standard to generate seven standard concentrations which were used to create a five-parameter logistic curve-fit standard curve with the xPONENT software (Luminex Corporation, Austin, TX, USA). Before quantifying cytokines, the high sensitivity bead panel was successfully validated and calibrated, showing a correct standard curve for each cytokine. Cytokines were determined in BALF as well as in serum.

Statistical analysis

Continuous data are reported as median ± interquartile range (IQR) or as mean ± standard deviation (SD), as appropriate. Normal distribution was tested using the Shapiro-Wilk test. To express comparisons between groups, Chi-squared test or Fisher’s exact test was used for categorical variables and the Mann-Whitney U test or independent t-test for continuous variables. The Bonferroni correction was used adjust p-values for multiple comparisons to avoid the risk of a type I error. P values of less than 0.05 were considered to be statistically significant and were based on two-sided hypothesis. All analyses were conducted using IBM SPSS Statistics for Windows, Version 25.0 (IBM Corporation, Armonk, NY, USA) and R Core Team, 2013; R version 4.0.3 (2020-10-10).

Results

Totally, 24 patients were included in this parallel cohort study. From one patient with pneumonitis, BALF could not be yielded due to bronchial collapse, and from one patient in the control group the serum
sample was lost. Demographic characteristics and bronchoscopy data are summarized in Table 1. The absolute volume of recovered BALF in the pneumonitis compared to the control group was 65.0 ± 75.0 ml and 110.0 ± 100.0 ml (p = 0.304), respectively, referring to a recovery rate of 38.2 ± 11.3% and 52.2 ± 15.8% (p = 0.112), respectively. Absolute cell count and differentiation in serum and in BALF are summarized in Table 2 and Table 3, respectively. Expectedly, the absolute number and percentage of lymphocytes in BALF were significantly higher in the pneumonitis compared to control group (each p = 0.004). However, CD4/CD8-ratios were comparable between groups (p = 0.436). Inversely, the portion of macrophages was significantly higher in the control group (p = 0.008). In serum of the pneumonitis group, C-reactive protein (CRP) was significantly higher (p = 0.039). Likewise, the blood leukocytes count was higher in the pneumonitis group compared to controls, albeit this difference was not statistically significant. Analysis of cytokines in serum and BALF are presented in Table 4 and Table 5, respectively. Whereas all investigated cytokines in serum were equally distributed between the groups, analysis of BALF revealed a significantly increased portion of IL-6 in the pneumonitis compared to the control group (adjusted p = 0.044). All other investigated cytokines in BALF did not discriminate between the groups.
|                               | Pneumonitis | Controls | p-value |
|-------------------------------|-------------|----------|---------|
| **Number**                    | 12 (50.0)   | 12 (50.0) |         |
| **Demographics**              |             |          |         |
| Female                        | 5 (41.7)    | 4 (33.3) |         |
| Age                           | 70.6 (61.5–76.1) | 73.8 (61.6–75.3) | 0.755 |
| **Smoking**                   |             |          |         |
| Never smoker                  | 3 (25.0)    | 6 (50.0) |         |
| Current smoker                | 1 (8.3)     | 1 (8.3)  |         |
| Ex-smoker                     | 8 (66.7)    | 5 (41.7) |         |
| **Pack years**                | 10.0 (0.0–40.0) | 3 (0.0–13.8) | 0.260 |
| **Medical history**           |             |          |         |
| Adenocarcinoma of the lung    | 5 (41.7)    | 0        | -       |
| Metastasized melanoma         | 7 (58.3)    | 0        | -       |
| **Administered ICI**          |             |          |         |
| Pembrolizumab                 | 6 (50.0)    | 0        | -       |
| Nivolumab                     | 2 (16.7)    | 0        | -       |
| Durvalumab                    | 1 (8.3)     | 0        | -       |
| Ipilimumab + Pembrolizumab    | 3 (25.0)    | 0        | -       |
| **Bronchoscopy data**         |             |          |         |
| BAL in [ml]                   | 200.0 (15.1)| 200.0 (28.9)| 1.000 |
| BAL ex [ml]                   | 65.0 (21.3) | 110.0 (32.4)| 0.304 |
| BAL recovery [%]              | 32.5 (11.4) | 60.0 (15.8)| 0.112 |
| BAL cell count [cells/µl]     | 195.8 (201.0)| 75.5 (80.8)| 0.528 |

Data are presented as n (%), median (IQR) or mean (SD), as appropriate

Abbreviations: BAL = bronchoalveolar lavage
Table 2
Cell count and differentiation in serum

|                | Pneumonitis | Controls | p-value |
|----------------|-------------|----------|---------|
| CRP [mg/l]     | 42.5 (80.1) | 4.3 (37.0) | 0.039*  |
| Leukocytes [G/l] | 7.0 (2.5)   | 6.4 (2.7) | 0.487   |
| Neutrophils [G/l] | 4.8 (2.2)   | 3.9 (2.4) | 0.314   |
| Monocytes [G/l]  | 0.7 (0.3)   | 0.6 (0.2) | 0.203   |
| Eosinophils [G/l] | 0.1 (0.2)   | 0.1 (0.2) | 1.000   |
| Basophils [G/l]  | 0.0 (0.0)   | 0.0 (0.0) | 0.346   |
| Lymphocytes [G/l] | 1.1 (0.4)   | 1.5 (0.6) | 0.080   |
| Neutrophils [%] | 73.3 (9.4)  | 64.6 (10.5) | 0.295  |
| Monocytes [%]   | 9.3 (5.5)   | 10.4 (2.7) | 1.000  |
| Eosinophils [%] | 1.9 (3.2)   | 2.2 (1.4)  | 1.000  |
| Basophils [%]   | 0.3 (0.3)   | 0.5 (0.4)  | 1.000  |
| Lymphocytes [%] | 14.5 (5.3)  | 23.1 (10.3) | 0.085  |

* = p < 0.05, adjusted for multiple comparisons using the Bonferroni correction method.

Data are presented as mean (SD).

Abbreviations: CRP = C-reactive protein
Table 3
Cell count and cell differentiation in BALF

|                | Pneumonitis        | Control            | p-value  |
|----------------|--------------------|--------------------|----------|
| Macrophages [/µl] | 74.7 (18.4–139.0)  | 52.5 (40.3–113.0)  | 1.000    |
| Lymphocytes [/µl]  | 66.9 (30.8–152.9)  | 4.0 (3.4–25.4)     | 0.004*   |
| Neutrophils [/µl]  | 10.0 (4.7–14.8)    | 1.0 (0.6–15.3)     | 0.244    |
| Eosinophils [/µl]  | 0.4 (0.0–3.7)      | 0.3 (0.0–2.4)      | 1.000    |
| CD4⁺ T-cells [/µl] | 31.8 (7.6–100.7)   | 0.0 (0.0–8.4)      | 0.038*   |
| CD8⁺ T-cells [/µl] | 18.9 (8.0–52.6)    | 0.0 (0.0–6.5)      | 0.006*   |
| CD4⁺/CD8⁺ ratio    | 1.4 (0.5–3.5)      | 5.8 (1.3–5.8)      | 0.436    |
| Macrophages [%]    | 49.5 (27.5–62.5)   | 88.0 (63.3–95.3)   | 0.008*   |
| Lymphocytes [%]    | 45.5 (132.0–64.0)  | 7.3 (3.9–13.4)     | 0.004*   |
| Neutrophils [%]    | 5.5 (3.0–7.5)      | 1.5 (0.5–10.3)     | 0.608    |
| Eosinophils [%]    | 0.8 (0.4–1.8)      | 1.0 (0.0–3.0)      | 0.813    |
| CD4⁺ T-cells [%]   | 54.3 (27.4–69.2)   | 60.1 (33.4–60.1)   | 0.758    |
| CD8⁺ T-cells [%]   | 21.7 (19.0–63.2)   | 17.2 (8.5–17.2)    | 0.436    |

* = p < 0.05, adjusted for multiple comparisons using the Bonferroni correction method.

Data are presented as median (IQR).

Abbreviations: BALF = bronchoalveolar lavage fluid
Table 4
Analysis of cytokines in serum

|                      | Pneumonitis   | Control      | p-value |
|----------------------|---------------|--------------|---------|
| IFN-γ [pg/ml]        | 11.4 (2.7–18.5) | 4.9 (1.8–9.4) | 0.316   |
| IL-1B [pg/ml]        | 0.5 (0.2–0.8)  | 0.2 (0.1–0.6) | 0.413   |
| IL-2 [pg/ml]         | 1.9 (0.9–4.2)  | 1.4 (1.1–1.9) | 0.697   |
| IL-4 [pg/ml]         | 9.0 (4.0–14.7) | 6.4 (2.2–11.6) | 0.260   |
| IL-5 [pg/ml]         | 3.8 (1.8–5.2)  | 3.1 (1.3–5.7) | 0.833   |
| IL-6 [pg/ml]         | 5.8 (1.8–11.1) | 3.5 (1.8–7.1) | 0.379   |
| IL-8 [pg/ml]         | 9.4 (7.8–12.8) | 7.1 (6.5–10.3) | 0.833   |
| IL-12p70 [pg/ml]     | 2.9 (0.6–6.2)  | 2.2 (1.0–4.6) | 0.786   |
| IL-13 [pg/ml]        | 5.5 (2.2–10.1) | 3.7 (1.2–7.6) | 0.316   |
| IL-17 [pg/ml]        | 3.5 (0.7–12.9) | 2.4 (0.6–8.6) | 0.695   |
| TNF-α [pg/ml]        | 5.9 (4.5–11.1) | 7.0 (4.6–8.9) | 0.833   |

* = p < 0.05

Data are presented as median (IQR).

Abbreviations: IFN-γ = Interferon gamma, IL = interleukin, TNF-α = tumor necrosis factor alpha
Table 5
Analysis of cytokines in BALF

| Cytokine  | Pneumonitis     | Control       | p-value |
|-----------|-----------------|---------------|---------|
| IFN-γ [pg/ml] | 0.8 (0.0–1.3)  | 0.1 (0.0–1.2) | 1.000   |
| IL-1B [pg/ml]  | 0.2 (0.1–0.3)  | 0.2 (0.1–0.8) | 1.000   |
| IL-2 [pg/ml]   | 0.4 (0.3–0.8)  | 0.6 (0.3–1.3) | 1.000   |
| IL-4 [pg/ml]   | 0.0 (0.0–0.4)  | 0.0 (0.0–0.3) | 1.000   |
| IL-5 [pg/ml]   | 0.4 (0.0–0.8)  | 0.2 (0.0–0.6) | 1.000   |
| IL-6 [pg/ml]   | 126.0 (14.6–248.9) | 1.9 (0.5–4.5) | 0.044*  |
| IL-8 [pg/ml]   | 40.4 (18.5–77.5) | 39.0 (9.2–68.9) | 1.000   |
| IL-12p70 [pg/ml] | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.000   |
| IL-13 [pg/ml]  | 0.0 (0.0–0.2)  | 0.3 (0.0–0.8) | 1.000   |
| IL-17 [pg/ml]  | 0.5 (0.5–0.7)  | 0.7 (0.3–0.7) | 1.000   |
| TNF-α [pg/ml]  | 3.0 (0.8–8.8)  | 0.8 (0.6–2.1) | 0.759   |

* = p < 0.05, adjusted for multiple comparisons using the Bonferroni correction method

Data are presented as median (IQR).

Abbreviations: IFN-γ = Interferon gamma, IL = interleukin, TNF-α = tumor necrosis factor alpha

Discussion

After introducing ICIs in modern cancer treatment regimens, a new entity of irAEs has emerged including ICI-associated pneumonitis [4]. Since the immunological mechanism is not fully understood and, thus, diagnosis of ICI-associated pneumonitis is not straightforward due to several differential diagnoses, the focus of this study was to assess cytokine profile in BALF and serum of patients with ICI-associated pneumonitis compared to a matched healthy control group. In serum, both cell counts and all investigated cytokines were expressed similarly between the groups. However, in BALF of patients with ICI-associated pneumonitis there was a significantly higher lymphocytes count and a significantly higher expression of IL-6 compared to the control group.

Expressed by Th2-cells, monocytes, macrophages, dendritic cells and bone marrow stroma, IL-6 is an important cytokine for vast inflammatory responses including induction of acute phase proteins (APP) and enhancement of T-cell proliferation as well as polarization of Th17-cells. Th17-cells are a subset of CD4-cells known to trigger massive inflammatory diseases with a tendency for autoimmune reactions [29]. Notably, in the present study, CD4/CD8 ratio in BALF was comparable between the groups, although one might have expected a lower ratio in the pneumonitis group. Possibly, the sample size was too small
to show a significant difference. Th17-cells reside mostly in tissues exposed to the external environment such as gastrointestinal tract, skin and respiratory tract, and express themselves cytokines, notably IL-17A, IL-21 and IL-22. Both, autoimmune diseases and chronic inflammatory disorders of the lung are suspected to arise from dysregulation of Th17-cells such as chronic obstructive pulmonary disease (COPD), bronchial asthma, rheumatoid arthritis (RA), chronic hypersensitivity pneumonitis and other forms of interstitial fibrosis [30–33]. In addition, in a mice model, recovery from acute lung injury in absence of Th17-cells was faster compared to those with Th17-positive cellular immune reaction [34]. It seems plausible that Th17-cells stimulated by IL-6 play an important role in the still vague pathogenesis of ICI-associated pneumonitis.

Although IL-6 levels in BALF of the pneumonitis group were significantly increased compared to healthy subjects in our study, their origin remains uncertain. According to a recent study by our group IL-6 was not significantly increased in BALF of patients with untreated lung cancer and other lung diseases (sarcoidosis, interstitial lung disease), deeming IL-6 appropriate as biomarker of unspecific inflammation [35]. Therefore, increased IL-6 levels in our study could originate from inflammation due to ICI-associated pneumonitis. However, enhanced and polarized through IL-6 expression, Th17-cells may serve as a more precise biomarker. Determining Th17-cell count, IL-17A, IL-21, and IL-22 in BALF and serum, respectively, might be indispensable to gain further knowledge about their role in immune-related pneumonitis. At least, there is one study showing significant association of elevated levels of IL-17 in BALF and serum of patients with ICI-associated pneumonitis [21].

Owed to the broad inflammatory response of IL-6, there is little use for IL-6 as single diagnostic tool. However, as important element of pathogenesis in several diseases, antibodies against IL-6 might be used as therapeutic approach. Initially used for treatment of RA, the anti-IL-6R antibody Tocilizumab has since been successfully approved for therapy of systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis [36]. Due to the importance of IL-6 in immune response, Tocilizumab may have the potential to play a similarly important role in regulation thereof, as there are numerous preclinical and clinical studies investigating further example of application such as giant cell arteritis, polymyalgia rheumatica and large vessel vasculitis [36]. In light of the significantly increased IL-6 levels in our study and potential starting point for therapy, one study in particular showed promising results. Patients with steroid-refractory ICI-associated pneumonitis showed significant clinical improvement upon administration of Tocilizumab [37], underlining our findings and the potential relevance of IL-6 in ICI-associated pneumonitis.

There are several limitations to this study. First, a relatively small number of patients treated with ICI paired with low incidence of ICI-associated pneumonitis resulted in a small sample size. Consequently, general validity of results is limited. Second, albeit BAL is widely accepted as valid tool for assessing the cellular composition of the alveolar compartment and, thus, for contributing to diagnosis of various lung diseases [38], it presents constraints owed to dilution necessary to acquire BALF. Therefore, lower cytokine readings in BALF may go undetected, which could skew data. Lastly, while comparing healthy
individuals and patients with ICI-associated pneumonitis, further distinctions of ICI-associated pneumonitis to other pulmonary diseases remain to be demonstrated.

**Conclusion**

Cytokine profile assessed through BAL shows promising potential for facilitating diagnosis and understanding of the pathophysiology of ICI-associated pneumonitis. As such, IL-6 seems to play a relevant role, which may herald also therapeutic implications for the use of Tocilizumab. In addition, importance of Th17-cells in pathogenesis of ICI-associated pneumonitis appears worthy of future investigations. Further studies have to be conducted to determine indications of cytokine analysis in BALF in patients with suspected ICI-associated pneumonitis.

**Abbreviations**

AIP = acute interstitial pneumonia  
APP = acute phase protein  
ARDS = acute respiratory distress syndrome  
BAL = bronchoalveolar lavage  
BALF = bronchoalveolar lavage fluid  
COPD = chronic obstructive pulmonary disease  
CRP = C-reactive protein  
CT = computed tomography  
CTLA-4 = cytotoxic T-lymphocyte-associated antigen 4  
HP = hypersensitivity pneumonitis  
ICI = immune-checkpoint inhibitor  
IFN-gamma = interferon gamma  
IL = interleukin  
ILD = interstitial lung disease  
IQR = interquartile range  
irAE = immune-related adverse events
Declarations

Ethics approval

This study followed guidelines and protocol of Swiss Ethics and was approved by the local ethic review committee (BASEC-ID 2017-02307 and 2018-01724).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests regarding this study.

Funding

The study was funded by an unrestricted grant from EMDO Stiftung. (https://stiftungen.stiftungschweiz.ch/organizations/emdo-stiftung).
Authors’ contributions

Study design (BK, AV, US, PB, MEV, DF), data collection (BK, AV, DF, DS, SW, PB, MEV, AW), data analysis (BK, PB, MEV, AV), drafting of the manuscript (BK, DF), approval of the final version of the manuscript (all authors)

Acknowledgements

We thank Dr Ulrike Held, Epidemiology, Biostatistics and Prevention Institute, University of Zurich for her statistical advice.

References

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug;363(8):711-23.
2. Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbé C, Hauschild A. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma? Melanoma Res. 2015 Dec;25(6):461-9.
3. Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017 04;21(1):89.
4. Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207-13.
5. Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016 Jun;10(3):183-93.
6. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec;2(12):1607-16.
7. Franzen D, Schad K, Dummer R, Russi EW. Severe acute respiratory distress syndrome due to ipilimumab. Eur Respir J. 2013 Sep;42(3):866-8.
8. Naidoo J, Wang X, Woo KM, lyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017 Mar;35(7):709-17.
9. Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med. 2018 06;6(6):472-78.
10. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taib M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer
11. Porcu M, De Silva P, Solinas C, Battaglia A, Schena M, Scartozzi M, et al. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers (Basel). 2019 Mar;11(3).

12. Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, et al. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clin Cancer Res. 2019 Mar;25(5):1557-63.

13. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 2010 Dec;62(12):3768-75.

14. Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam. 2011;2011:908468.

15. Ricker LJ, Kijlstra A, Kessels AG, de Jager W, Liem AT, Hendrikse F, et al. Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS One. 2011 Apr;6(4):e19141.

16. Corcoran AT, Yoshimura N, Tyagi V, Jacobs B, Leng W, Tyagi P. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013 Feb;31(1):241-6.

17. Hosoki K, Ying S, Corrigan C, Qi H, Kurosya Y, Jennings K, et al. Analysis of a Panel of 48 Cytokines in BAL Fluids Specifically Identifies IL-8 Levels as the Only Cytokine that Distinguishes Controlled Asthma from Uncontrolled Asthma, and Correlates Inversely with FEV1. PLoS One. 2015;10(5):e0126035.

18. Ernst A, Silvestri GA, Johnstone D. Interventional Pulmonary Procedures: Guidelines from the American College of Chest Physicians. Chest. 2003 2003/05/01/;123(5):1693-94.

19. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e142S-e65S.

20. Kumar R, Gupta N. Role of bronchoscopy in evaluation of cases with sputum smear negative pulmonary tuberculosis, interstitial lung disease and lung malignancy: A retrospective study of 712 cases. Indian Journal of Tuberculosis. 2015 2015/01/01/;62(1):36-42.

21. Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W, et al. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett. 2020 Jul;20(1):611-22.

22. Valaperti A, Bezel P, Vonow-Eisenring M, Franzen D, Steiner UC. Variability of cytokine concentration in whole blood serum and bronchoalveolar lavage over time. Cytokine. 2019 Jul;123:154768.

23. Rennard SI, Aalbers R, Bleecker E, Klech H, Rosenwasser L, Olivieri D, et al. Bronchoalveolar lavage: performance, sampling procedure, processing and assessment. Eur Respir J Suppl. 1998 Mar;26:13S-15S.
24. Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med. 2007 Oct;28(5):475-85.

25. Kondo A. [Drug-induced pneumonitis]. Kekkaku. 1999 Jan;74(1):33-41.

26. Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003 Oct;58(10):872-5.

27. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012 May;13:39.

28. Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 Apr;7(1):112.

29. Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt's Essential Immunology. 13th Edition ed. Chichester, West Sussex: John Wiley & Sons, Inc.; 2017.

30. Nembrini C, Marsland BJ, Kopf M. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol. 2009 May;123(5):986-94; quiz 95-6.

31. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013 Jan;8:477-512.

32. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and pathology. Eur J Immunol. 2017 04;47(4):607-14.

33. Zhang J, Wang D, Wang L, Wang S, Roden AC, Zhao H, et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2019 03;316(3):L487-L97.

34. Wang L, Wang X, Tong L, Wang J, Dou M, Ji S, et al. Recovery from acute lung injury can be regulated via modulation of regulatory T cells and Th17 cells. Scand J Immunol. 2018 Nov;88(5):e12715.

35. Bezel P, Valaperti A, Steiner UC, Scholtze D, Wieser S, Vonow-Eisenring M, et al. Evaluation of Cytokines in the Tumor Microenvironment of Lung Cancer Using Bronchoalveolar Lavage Fluid Analysis. Cancer Immunology, Immunotherapy.in press.

36. Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017 09;13(9):1972-88.

37. Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019 Apr;25(3):551-57.

38. Gharsalli H, Mlika M, Sahnoun I, Maalej S, Douik El Gharbi L, Mezni FE. The utility of bronchoalveolar lavage in the evaluation of interstitial lung diseases: A clinicopathological perspective. Semin Diagn Pathol. 2018 Sep;35(5):280-87.